Bradley J. Willcox
Research Subjects
Research Interests
Bradley J. Willcox has a total of 83 co-authors. Here are the top co-authors by number of shared publications:
- Brian J. Morris
School of Medical Sciences, University of Sydney, Sydney, NSW, Australia
4 shared publications Randi Chen
Center of Biomedical Research Excellence for Translational Research on Aging and Department of Research, Kuakini Medical Center , Honolulu, Hawaii , USA
4 shared publicationsTimothy A. Donlon
Center of Biomedical Research Excellence for Translational Research on Aging, Kuakini Medical Center Honolulu Hawaii USA
4 shared publicationsBrian J. Morris
Honolulu Heart Program/Honolulu-Asia Aging Study, Kuakini Medical Center, Honolulu, HI, United States; John A. Burns School of Medicine, University of Hawaii, Honolulu, HI, United States; School of Medical Sciences and Bosch Institute, University of Sydney, Sydney, NSW, Australia
3 shared publicationsD. Craig Willcox
Center of Biomedical Research Excellence for Translational Research on Aging, Kuakini Medical Center Honolulu Hawaii USA
3 shared publications- Donald Craig Willcox
Department of Human Welfare, Okinawa International University, 2-6-1 Ginowan, Ginowan City, Okinawa, Japan
3 shared publications
Latest Publications
- Open Access
- 30 September 2024
- Published by Elsevier in Lung Cancer
- Vol. 198, 107971
Association of alcohol with lung cancer risk in men with different growth hormone receptor genotypes
- 30 September 2024
- Published by Elsevier in Lung Cancer
- Vol. 198, 107971
Open AccessAssociation of alcohol with lung cancer risk in men with different growth hormone receptor genotypes
- Open Access
- 15 May 2024
- Published by Wiley in Aging Cell
- Vol. 23 (8) , e14191
Circulating microRNA profile of long‐lived Okinawans identifies novel potential targets for optimizing lifespan and health span
Nonagenarians and centenarians serve as successful examples of aging and extended longevity, showcasing robust regulation of biological mechanisms and homeostasis. Given that human longevity is a complex field of study that navigates molecular and biological mechanisms influencing aging, we hypothesized that microRNAs, a class of small noncoding RNAs implicated in regulating gene expression at the post‐transcriptional level, are differentially regulated in the circulatory system of young, middle‐aged, and nonagenarian individuals. We sequenced circulating microRNAs in Okinawan males and females 90 years of age accounting for FOXO3 genetic variations of single nucleotide polymorphism (SNP) rs2802292 (TT ‐ common vs. GT ‐ longevity) and validated the findings through RT‐qPCR. We report five microRNAs exclusively upregulated in both male and female nonagenarians with the longevity genotype, play predictive functional roles in TGF‐β, FoxO, AMPK, Pi3K‐Akt, and MAPK signaling pathways. Our findings suggest that these microRNAs upregulated in nonagenarians may provide novel insight into enhanced lifespan and health span. This discovery warrants further exploration into their roles in human aging and longevity.
- 15 May 2024
- Published by Wiley in Aging Cell
- Vol. 23 (8) , e14191
Open AccessCirculating microRNA profile of long‐lived Okinawans identifies novel potential targets for optimizing lifespan and health span
Nonagenarians and centenarians serve as successful examples of aging and extended longevity, showcasing robust regulation of biological mechanisms and homeostasis. Given that human longevity is a complex field of study that navigates molecular and biological mechanisms influencing aging, we hypothesized that microRNAs, a class of small noncoding RNAs implicated in regulating gene expression at the post‐transcriptional level, are differentially regulated in the circulatory system of young, middle‐aged, and nonagenarian individuals. We sequenced circulating microRNAs in Okinawan males and females 90 years of age accounting for FOXO3 genetic variations of single nucleotide polymorphism (SNP) rs2802292 (TT ‐ common vs. GT ‐ longevity) and validated the findings through RT‐qPCR. We report five microRNAs exclusively upregulated in both male and female nonagenarians with the longevity genotype, play predictive functional roles in TGF‐β, FoxO, AMPK, Pi3K‐Akt, and MAPK signaling pathways. Our findings suggest that these microRNAs upregulated in nonagenarians may provide novel insight into enhanced lifespan and health span. This discovery warrants further exploration into their roles in human aging and longevity.
- 17 November 2022
- Published by Elsevier in Journal of Clinical Lipidology
- Vol. 17 (1) , 131-141
Circulating plasma phospholipid fatty acid levels as a biomarker of habitual dietary fat intake: The INTERMAP/INTERLIPID Study
- 17 November 2022
- Published by Elsevier in Journal of Clinical Lipidology
- Vol. 17 (1) , 131-141
Circulating plasma phospholipid fatty acid levels as a biomarker of habitual dietary fat intake: The INTERMAP/INTERLIPID Study
- Open Access
- 1 August 2022
- Published by Oxford University Press (OUP) in The Journals of Gerontology, Series A: Biological Sciences and Medical Sciences
- Vol. 77 (8) , 1479-1484
FOXO3, a Resilience Gene: Impact on Lifespan, Healthspan, and Deathspan
Oliver Wendell Holmes is purported to have said, “Old age is always fifteen years older than I am.” Given recent rapid advances in understanding the aging process – from molecular, cellular, tissue, organ, to whole body aging – Holmes appears prescient. There is little doubt that people age at different rates and in different ways ( 1). If one could indeed remain 15 to 20 years “biologically younger” than their chronological age and delay the onset of aging-related chronic diseases and disability, that would be quite an achievement for the individual and society ( 2). This, of course, assumes that if lifespan is prolonged, one also compresses morbidity, resulting in a longer healthspan, not a longer “deathspan” (ie, poor quality of life from extra years of severe disease and incapacitation), see Figure 1.
- 1 August 2022
- Published by Oxford University Press (OUP) in The Journals of Gerontology, Series A: Biological Sciences and Medical Sciences
- Vol. 77 (8) , 1479-1484
Open AccessFOXO3, a Resilience Gene: Impact on Lifespan, Healthspan, and Deathspan
Oliver Wendell Holmes is purported to have said, “Old age is always fifteen years older than I am.” Given recent rapid advances in understanding the aging process – from molecular, cellular, tissue, organ, to whole body aging – Holmes appears prescient. There is little doubt that people age at different rates and in different ways ( 1). If one could indeed remain 15 to 20 years “biologically younger” than their chronological age and delay the onset of aging-related chronic diseases and disability, that would be quite an achievement for the individual and society ( 2). This, of course, assumes that if lifespan is prolonged, one also compresses morbidity, resulting in a longer healthspan, not a longer “deathspan” (ie, poor quality of life from extra years of severe disease and incapacitation), see Figure 1.
- Open Access
- 5 July 2020
- Published by MDPI AG in Marine Drugs
- Vol. 18 (7) , 351
Astaxanthin as a Putative Geroprotector: Molecular Basis and Focus on Brain Aging
In recent years, the scientific interest in natural compounds with geroprotective activities has grown exponentially. Among the various naturally derived molecules, astaxanthin (ASX) represents a highly promising candidate geroprotector. By virtue of the central polyene chain, ASX acts as a scavenger of free radicals in the internal membrane layer and simultaneously controls oxidation on the membrane surface. Moreover, several studies have highlighted ASX’s ability to modulate numerous biological mechanisms at the cellular level, including the modulation of transcription factors and genes directly linked to longevity-related pathways. One of the main relevant evolutionarily-conserved transcription factors modulated by astaxanthin is the forkhead box O3 gene (FOXO3), which has been recognized as a critical controller of cell fate and function. Moreover, FOXO3 is one of only two genes shown to robustly affect human longevity. Due to its tropism in the brain, ASX has recently been studied as a putative neuroprotective molecule capable of delaying or preventing brain aging in different experimental models of brain damage or neurodegenerative diseases. Astaxanthin has been observed to slow down brain aging by increasing brain-derived neurotrophic factor (BDNF) levels in the brain, attenuating oxidative damage to lipids, protein, and DNA and protecting mitochondrial functions. Emerging data now suggest that ASX can modulate Nrf2, FOXO3, Sirt1, and Klotho proteins that are linked to longevity. Together, these mechanisms provide support for a role of ASX as a potential geroneuroprotector.
- 5 July 2020
- Published by MDPI AG in Marine Drugs
- Vol. 18 (7) , 351
Open AccessAstaxanthin as a Putative Geroprotector: Molecular Basis and Focus on Brain Aging
In recent years, the scientific interest in natural compounds with geroprotective activities has grown exponentially. Among the various naturally derived molecules, astaxanthin (ASX) represents a highly promising candidate geroprotector. By virtue of the central polyene chain, ASX acts as a scavenger of free radicals in the internal membrane layer and simultaneously controls oxidation on the membrane surface. Moreover, several studies have highlighted ASX’s ability to modulate numerous biological mechanisms at the cellular level, including the modulation of transcription factors and genes directly linked to longevity-related pathways. One of the main relevant evolutionarily-conserved transcription factors modulated by astaxanthin is the forkhead box O3 gene (FOXO3), which has been recognized as a critical controller of cell fate and function. Moreover, FOXO3 is one of only two genes shown to robustly affect human longevity. Due to its tropism in the brain, ASX has recently been studied as a putative neuroprotective molecule capable of delaying or preventing brain aging in different experimental models of brain damage or neurodegenerative diseases. Astaxanthin has been observed to slow down brain aging by increasing brain-derived neurotrophic factor (BDNF) levels in the brain, attenuating oxidative damage to lipids, protein, and DNA and protecting mitochondrial functions. Emerging data now suggest that ASX can modulate Nrf2, FOXO3, Sirt1, and Klotho proteins that are linked to longevity. Together, these mechanisms provide support for a role of ASX as a potential geroneuroprotector.
- 1 September 2018
- Published by Elsevier in Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease
- Vol. 1865 (7) , 1718-1744
Genetic and epigenetic regulation of human aging and longevity
- 1 September 2018
- Published by Elsevier in Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease
- Vol. 1865 (7) , 1718-1744
Genetic and epigenetic regulation of human aging and longevity
- 21 April 2018
- Published by Oxford University Press (OUP) in The Journals of Gerontology, Series A: Biological Sciences and Medical Sciences
- Vol. 73 (11) , 1448-1452
Minimal Shortening of Leukocyte Telomere Length Across Age Groups in a Cross-Sectional Study for Carriers of a Longevity-Associated FOXO3 Allele
FOXO3 is one of the most prominent genes demonstrating a consistently reproducible genetic association with human longevity. The mechanisms by which these individual gene variants confer greater organismal lifespan are not well understood. We assessed the effect of longevity-associated FOXO3 alleles on age-related leukocyte telomere dynamics in a cross-sectional study comprising of samples from 121 healthy Okinawan-Japanese donors aged 21–95 years. We found that telomere length for carriers of the longevity associated allele of FOXO3 single nucleotide polymorphism rs2802292 displayed no significant correlation with age, an effect that was most pronounced in older (>50) participants. This is the first validated longevity gene variant identified to date showing an association with negligible loss of telomere length with age in humans in a cross sectional study. Reduced telomere attrition may be a key mechanism for the longevity-promoting effect of the FOXO3 genotype studied.
- 21 April 2018
- Published by Oxford University Press (OUP) in The Journals of Gerontology, Series A: Biological Sciences and Medical Sciences
- Vol. 73 (11) , 1448-1452
Minimal Shortening of Leukocyte Telomere Length Across Age Groups in a Cross-Sectional Study for Carriers of a Longevity-Associated FOXO3 Allele
FOXO3 is one of the most prominent genes demonstrating a consistently reproducible genetic association with human longevity. The mechanisms by which these individual gene variants confer greater organismal lifespan are not well understood. We assessed the effect of longevity-associated FOXO3 alleles on age-related leukocyte telomere dynamics in a cross-sectional study comprising of samples from 121 healthy Okinawan-Japanese donors aged 21–95 years. We found that telomere length for carriers of the longevity associated allele of FOXO3 single nucleotide polymorphism rs2802292 displayed no significant correlation with age, an effect that was most pronounced in older (>50) participants. This is the first validated longevity gene variant identified to date showing an association with negligible loss of telomere length with age in humans in a cross sectional study. Reduced telomere attrition may be a key mechanism for the longevity-promoting effect of the FOXO3 genotype studied.
- Open Access
- 19 April 2018
- Published by MDPI AG in Geriatrics
- Vol. 3 (2) , 21
Effects of Walking on Coronary Heart Disease in Elderly Men with Diabetes
Previous studies have shown that walking is associated with increased longevity and a reduced risk of cardiovascular and age-related diseases. Whether walking benefits individuals with diabetes who are at high risk of coronary heart disease (CHD) remains to be determined. The objective of this study is to examine the association between walking and risk of CHD among elderly men with and without diabetes. Walking data was assessed in 2732 men aged 71 to 93 years participating in the Honolulu Heart Program from 1991–1993. Study participants were initially without disabilities and free of prevalent CHD. Men were then followed for incident CHD for up to 7 years. For men with diabetes who walked 1.5 miles/day, incidence of CHD was similar in men with and without diabetes (12.2 vs. 9.1/1000 person-years, p = 0.46). While risk of CHD declined significantly with increasing walking distance in men with diabetes after age and risk factor adjustment (p = 0.043, p = 0.025), associations in those without diabetes were weaker (p = 0.070, p = 0.10). These findings suggest that among elderly men with diabetes who are capable of physical activity, walking reduces CHD risk to levels similar to when diabetes is absent. Walking is an easy, safe and accessible form of physical activity that may have marked health benefits for elderly men with diabetes.
- 19 April 2018
- Published by MDPI AG in Geriatrics
- Vol. 3 (2) , 21
Open AccessEffects of Walking on Coronary Heart Disease in Elderly Men with Diabetes
Previous studies have shown that walking is associated with increased longevity and a reduced risk of cardiovascular and age-related diseases. Whether walking benefits individuals with diabetes who are at high risk of coronary heart disease (CHD) remains to be determined. The objective of this study is to examine the association between walking and risk of CHD among elderly men with and without diabetes. Walking data was assessed in 2732 men aged 71 to 93 years participating in the Honolulu Heart Program from 1991–1993. Study participants were initially without disabilities and free of prevalent CHD. Men were then followed for incident CHD for up to 7 years. For men with diabetes who walked 1.5 miles/day, incidence of CHD was similar in men with and without diabetes (12.2 vs. 9.1/1000 person-years, p = 0.46). While risk of CHD declined significantly with increasing walking distance in men with diabetes after age and risk factor adjustment (p = 0.043, p = 0.025), associations in those without diabetes were weaker (p = 0.070, p = 0.10). These findings suggest that among elderly men with diabetes who are capable of physical activity, walking reduces CHD risk to levels similar to when diabetes is absent. Walking is an easy, safe and accessible form of physical activity that may have marked health benefits for elderly men with diabetes.
- 1 January 2018
- Published by Elsevier
- Vol. 127, 193-212
FOXO3 and Exceptional Longevity: Insights From Hydra to Humans
- 1 January 2018
- Published by Elsevier
- Vol. 127, 193-212
FOXO3 and Exceptional Longevity: Insights From Hydra to Humans
- 1 July 2017
- Published by Elsevier in Mechanisms of Ageing and Development
- Vol. 165, 75-79
Demographic, phenotypic, and genetic characteristics of centenarians in Okinawa and Japan: Part 1—centenarians in Okinawa
- 1 July 2017
- Published by Elsevier in Mechanisms of Ageing and Development
- Vol. 165, 75-79
Demographic, phenotypic, and genetic characteristics of centenarians in Okinawa and Japan: Part 1—centenarians in Okinawa